We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
da Vinci 5 Expands Globally: Can ISRG Beat Overseas Cost Hurdles?
Read MoreHide Full Article
Key Takeaways
ISRG is rolling out da Vinci 5 overseas, with early adoption led by academic hospitals in Europe and Japan.
ISRG says pricing pressure, budgets, and reimbursement scrutiny are slowing adoption abroad.
ISRG is using leasing and flexible configurations to support utilization and recurring revenues abroad.
Intuitive Surgical’s (ISRG - Free Report) da Vinci 5 is in early stages of international rollout, which represents long-term opportunity for the company. However, the rollout may face potential hurdles in the near term. Management has reiterated that da Vinci 5 is central to ISRG’s growth strategy, designed to drive higher utilization through improved efficiency, surgeon autonomy and integrated digital capabilities.
During the third quarter, Intuitive Surgical highlighted that it is making progress in advancing regulatory clearances and early commercial activity outside the United States. The company has emphasized it will follow a measured, country-specific trajectory for international adoption. ISRG stated that currently da Vinci 5 is being typically adopted by large academic and flagship hospitals, particularly in Europe and Japan. The company believes that customers are currently evaluating clinical and economic benefits before committing to broader fleet upgrades.
However, Intuitive Surgical was clear that pricing sensitivity and capital budget constraints remain key challenges internationally. Government-funded healthcare systems, especially in parts of Europe and Japan, continue to scrutinize capital expenditures, extending sales cycles and slowing system placements compared to the U.S. market. Management also acknowledged ongoing competitive and reimbursement-related pressures in China, which further complicate near-term expansion.
Intuitive Surgical is following a portfolio-based approach amid these challenges, leveraging leasing structures and alternative configurations to improve affordability while maintaining customer engagement. On its third-quarter earnings call, the company highlighted solid growth in utilization in several international markets that will likely support recurring instruments and accessories revenues even when capital placements lag.
Although ISRG may face some near-term challenges in the adoption of the da Vinci 5, the latest addition to the company’s surgical robotics portfolio holds significant long-term potential to expand its international footprint. However, execution abroad will hinge on navigating cost sensitivity and aligning system economics with local healthcare funding realities.
Peer Update
Zimmer Biomet (ZBH - Free Report) is steadily expanding its international footprint while advancing the adoption of its ROSA robotic surgery platform. During the third quarter, Zimmer Biomet reported solid international growth driven by new product introductions, although its performance was tempered by near-term volatility in select emerging markets. Zimmer Biomet continues to invest in leadership and commercial execution across overseas geographies to strengthen long-term growth.
ROSA remains a central pillar of the company’s technology strategy, with strong global placements and rising utilization, particularly in knee procedures. Notably, U.S. ROSA accounts now perform more than half of their knee implants robotically, a benchmark Zimmer Biomet aims to replicate internationally over time. The company is also preparing to launch enhanced ROSA capabilities, including ROSA with OptimiZe, to support broader adoption across global markets. Overall, Zimmer Biomet views international expansion of ROSA as a multi-year opportunity, balancing near-term market challenges with sustained investment in robotics-driven growth.
Stereotaxis (STXS - Free Report) is making significant progress with its GenesisX robotic surgery platform, a next-generation solution designed to expand access to robotic electrophysiology procedures. In the second quarter of 2025, Stereotaxis’ GenesisX secured CE Mark approval in Europe, and the first commercial system was manufactured, with FDA clearance expected later this year.
Initial hospital installations are likely to have started in Europe in 2025, and a full U.S. and EU launch is expected in 2026. GenesisX is engineered to avoid costly lab construction, lowering barriers to adoption. With second-quarter operating expenses steady at $6 million, Stereotaxis plans disciplined reinvestment in salesforce expansion and catheter-driven recurring revenues to support commercialization.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have gained 9.7% in the past six months compared with an 12.8% increase for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 58.13, above the industry average. But it is still lower than its five-year median of 71.52. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies an 11.1% rise from the year-ago period’s level.
Image: Shutterstock
da Vinci 5 Expands Globally: Can ISRG Beat Overseas Cost Hurdles?
Key Takeaways
Intuitive Surgical’s (ISRG - Free Report) da Vinci 5 is in early stages of international rollout, which represents long-term opportunity for the company. However, the rollout may face potential hurdles in the near term. Management has reiterated that da Vinci 5 is central to ISRG’s growth strategy, designed to drive higher utilization through improved efficiency, surgeon autonomy and integrated digital capabilities.
During the third quarter, Intuitive Surgical highlighted that it is making progress in advancing regulatory clearances and early commercial activity outside the United States. The company has emphasized it will follow a measured, country-specific trajectory for international adoption. ISRG stated that currently da Vinci 5 is being typically adopted by large academic and flagship hospitals, particularly in Europe and Japan. The company believes that customers are currently evaluating clinical and economic benefits before committing to broader fleet upgrades.
However, Intuitive Surgical was clear that pricing sensitivity and capital budget constraints remain key challenges internationally. Government-funded healthcare systems, especially in parts of Europe and Japan, continue to scrutinize capital expenditures, extending sales cycles and slowing system placements compared to the U.S. market. Management also acknowledged ongoing competitive and reimbursement-related pressures in China, which further complicate near-term expansion.
Intuitive Surgical is following a portfolio-based approach amid these challenges, leveraging leasing structures and alternative configurations to improve affordability while maintaining customer engagement. On its third-quarter earnings call, the company highlighted solid growth in utilization in several international markets that will likely support recurring instruments and accessories revenues even when capital placements lag.
Although ISRG may face some near-term challenges in the adoption of the da Vinci 5, the latest addition to the company’s surgical robotics portfolio holds significant long-term potential to expand its international footprint. However, execution abroad will hinge on navigating cost sensitivity and aligning system economics with local healthcare funding realities.
Peer Update
Zimmer Biomet (ZBH - Free Report) is steadily expanding its international footprint while advancing the adoption of its ROSA robotic surgery platform. During the third quarter, Zimmer Biomet reported solid international growth driven by new product introductions, although its performance was tempered by near-term volatility in select emerging markets. Zimmer Biomet continues to invest in leadership and commercial execution across overseas geographies to strengthen long-term growth.
ROSA remains a central pillar of the company’s technology strategy, with strong global placements and rising utilization, particularly in knee procedures. Notably, U.S. ROSA accounts now perform more than half of their knee implants robotically, a benchmark Zimmer Biomet aims to replicate internationally over time. The company is also preparing to launch enhanced ROSA capabilities, including ROSA with OptimiZe, to support broader adoption across global markets. Overall, Zimmer Biomet views international expansion of ROSA as a multi-year opportunity, balancing near-term market challenges with sustained investment in robotics-driven growth.
Stereotaxis (STXS - Free Report) is making significant progress with its GenesisX robotic surgery platform, a next-generation solution designed to expand access to robotic electrophysiology procedures. In the second quarter of 2025, Stereotaxis’ GenesisX secured CE Mark approval in Europe, and the first commercial system was manufactured, with FDA clearance expected later this year.
Initial hospital installations are likely to have started in Europe in 2025, and a full U.S. and EU launch is expected in 2026. GenesisX is engineered to avoid costly lab construction, lowering barriers to adoption. With second-quarter operating expenses steady at $6 million, Stereotaxis plans disciplined reinvestment in salesforce expansion and catheter-driven recurring revenues to support commercialization.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have gained 9.7% in the past six months compared with an 12.8% increase for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 58.13, above the industry average. But it is still lower than its five-year median of 71.52. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies an 11.1% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.